Research
The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials.
Psychiatry research – September 01, 2024
Summary
MDMA, when combined with therapy, shows remarkable promise in treating Posttraumatic Stress Disorder (PTSD). A comprehensive meta-analysis of seven clinical trials found that this treatment significantly reduced PTSD symptoms compared to placebo groups. While some patients experienced mild side effects like muscle tension, the benefits of 3,4-Methylenedioxymethamphetamine therapy outweighed risks in controlled settings.
Abstract
3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is one of the most widely used illicit substances worldwide. MDMA-assisted psy...
Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – September 01, 2024
Summary
Rapid relief from the inability to feel pleasure (anhedonia) may be possible with ketamine therapy. This groundbreaking treatment shows promise for both major depressive disorder and bipolar depression patients. Studies reveal that a single dose can quickly restore the brain's ability to experience joy and reward, with effects lasting several days to weeks. Esketamine nasal spray and IV ketamine both demonstrated significant improvements in mood and emotional responsiveness.
Abstract
Ketamine, an N-methyl-D-aspartate receptor antagonist, is a racemic mixture of esketamine and arketamine used to treat unipolar and bipolar depress...
Sedoanalgesia With Ketamine in the Emergency Department: Factors Associated With Unsatisfactory Effectiveness.
Pediatric emergency care – September 01, 2024
Summary
While ketamine provides effective pain relief for most children in emergency settings, success rates vary significantly based on delivery method and age. Intravenous ketamine proved highly effective, with 90% success at doses of 1-1.5 mg/kg. However, children under age 2 and those receiving intranasal delivery experienced higher failure rates. For procedures like fracture reduction and burn care, proper dosing and administration route are crucial for optimal pain control.
Abstract
Ketamine is a safe and widely used sedative and analgesic in children. The purpose of this study is to evaluate the response to sedoanalgesia for p...
AA, Bill Wilson, Carl Jung and LSD.
The Journal of analytical psychology – September 01, 2024
Summary
In a fascinating historical intersection, AA founder Bill Wilson explored LSD's potential to help alcoholics achieve spiritual awakening. After witnessing promising results in treating alcohol use disorder, Wilson wrote to psychiatrist Carl Jung about using psychedelics to help those struggling with AA's spiritual elements. Jung never responded, passing away shortly after receiving the letter.
Abstract
Alcoholics Anonymous (AA) is an established resource for people suffering from alcohol use disorder (AUD). However, Bill Wilson, the co-founder of ...
Evaluation of thoracic sympathetic ganglion block as a predictor for response to ketamine infusion therapy and spinal cord stimulation in patients with chronic upper extremity pain.
Pain medicine (Malden, Mass.) – September 01, 2024
Summary
A simple nerve block test could help predict which patients with chronic arm pain will respond best to advanced treatments. Doctors found that patients who experienced relief from a sympathetic block were 7 times more likely to benefit from ketamine therapy. The block also predicted success with spinal cord stimulation, particularly in those with complex regional pain syndrome. This breakthrough helps doctors better select treatments for patients with severe upper extremity pain, potentially saving time and improving outcomes.
Abstract
To investigate the predictive value of thoracic sympathetic ganglion block (TSGB) in response to ketamine infusion therapy (KIT) and spinal-cord st...
Role of oxidative phosphorylation in the antidepressant effects of arketamine via the vagus nerve-dependent spleen-brain axis.
Neurobiology of disease – September 01, 2024
Summary
A groundbreaking discovery reveals how the body's energy production system plays a key role in treating depression. Scientists found that arketamine's antidepressant effects work through a fascinating connection between the spleen and brain, linked by the vagus nerve. This pathway relies on oxidative phosphorylation and transforming growth factor β1 to improve mood and behavior. The spleen-brain axis appears crucial for the treatment's success.
Abstract
Arketamine, the (R)-enantiomer of ketamine, exhibits antidepressant-like effects in mice, though the precise molecular mechanisms remain elusive. I...
The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).
Journal of affective disorders – September 01, 2024
Summary
While ketamine shows promise for treatment-resistant depression, new data from FDA adverse event reports reveals contrasting safety profiles between ketamine and esketamine. Ketamine showed higher rates of substance misuse reports, while esketamine actually had lower rates of drug abuse and dependence. This analysis of FAERS data helps inform the ongoing discussion about abuse liability in depression treatments.
Abstract
Ketamine and esketamine have been proven to be effective in treating adults with treatment resistant depression (TRD). Preliminary evidence indicat...
Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders.
Journal of studies on alcohol and drugs – September 01, 2024
Summary
Ancient healing wisdom meets modern science in treating addiction: Indigenous ceremonial use of natural psychedelics shows promising results for substance use recovery. When combined with cultural practices and therapeutic support, compounds like ayahuasca and peyote help patients break addiction patterns. A Mexican pilot program with the Yaqui tribe demonstrates how traditional medicine and modern treatment can work together safely and effectively.
Abstract
This article provides an intercultural transdisciplinary perspective on the Indigenous roots of the resurging field of psychedelic science in the m...
Exploring ketamine's reinforcement, cue-induced reinstatement, and nucleus accumbens cFos activation in male and female long evans rats.
Neuropharmacology – September 01, 2024
Summary
Ketamine's therapeutic potential comes with important considerations about addiction risk. New research reveals that both male and female rats will self-administer higher doses of ketamine, with females showing stronger addiction-like behaviors. The dose-response relationship suggests safer use at lower doses. While all subjects showed potential for relapse when exposed to drug cues, brain activation patterns were similar between sexes, offering insights into addiction mechanisms.
Abstract
Ketamine (KET), a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, has rapid onset of antidepressant effects in Treatment-Resistant...
Modification of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method targeting lysergic acid diethylamide (LSD) and its primary metabolite (OH-LSD) to include nine LSD analogs.
Journal of forensic sciences – September 01, 2024
Summary
Scientists developed an improved automated testing method to detect LSD and its newer chemical variants in urine samples. Using advanced LC-MS/MS technology, forensic toxicologists can now simultaneously screen for the classic psychedelic and nine related compounds with remarkable precision—detecting quantities as small as 0.1 nanograms per milliliter. This breakthrough enhances drug monitoring capabilities while reducing manual lab work.
Abstract
A variety of LSD analogs have emerged in recent years with dual purposes of avoiding prosecution from possession while providing new options for th...
Impact of Prolonged Continuous Ketamine Infusions in Critically Ill Children: A Prospective Cohort Study.
Paediatric drugs – September 01, 2024
Summary
Prolonged ketamine infusion in critically ill children shows mixed results: while improving sedation levels by 8%, it's linked to higher delirium rates. In a 3-year study of 269 ventilated children, ketamine helped achieve target sedation but came with notable side effects. 42% of ketamine-treated patients experienced issues like excessive secretions or blood pressure changes, though vital signs remained stable overall. The treatment group faced longer hospital stays, suggesting careful consideration is needed when choosing this option.
Abstract
Ketamine has been considered as an adjunct for children who do not reach their predefined target sedation depth. However, there is limited evidence...
Pretreatment Brain White Matter Integrity Associated With Neuropathic Pain Relief and Changes in Temporal Summation of Pain Following Ketamine.
The journal of pain – September 01, 2024
Summary
Brain structure may predict how well ketamine treats chronic nerve pain. New research shows that the integrity of white matter pathways, particularly in the default mode network and pain control regions like the periaqueductal gray, correlates with how effectively ketamine reduces neuropathic pain and pain sensitivity in patients.
Abstract
Neuropathic pain (NP) is a prevalent condition often associated with heightened pain responsiveness suggestive of central sensitization. Neuroimagi...
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.
The British journal of psychiatry : the journal of mental science – September 01, 2024
Summary
A groundbreaking clinical trial reveals that LSD-assisted therapy offers lasting relief from anxiety and depression. Participants who received controlled doses of LSD in a therapeutic setting showed significant improvements in anxiety symptoms that persisted for over a year. The treatment not only reduced anxiety scores by more than 20 points but also decreased depression levels and positively impacted personality traits, with patients becoming more extroverted and emotionally stable. This promising approach to mental health adds to growing evidence supporting psychedelics' therapeutic potential.
Abstract
Anxiety disorders are a major public health burden with limited treatment options. We investigated the long-term safety and efficacy of lysergic ac...
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.
Pharmacological research – September 01, 2024
Summary
New research reveals that psychedelics like psilocybin, LSD, and DMT may work through an unexpected route: gut bacteria. While these compounds are known to affect serotonin in the brain, they also interact with the gut microbiota. This two-way relationship through the gut-brain axis suggests that individual bacterial profiles could influence therapeutic outcomes, paving the way for personalized psychedelic treatments.
Abstract
Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around thei...
Jung, the Rebirth Motif and Psychedelics I: Documenting Jung's Contact with the British Pioneers.
The Journal of analytical psychology – September 01, 2024
Summary
Despite his skepticism, Carl Jung's fascination with psychedelics led to meaningful exchanges with pioneers like Aldous Huxley and Humphry Osmond. British psychiatrist Ronald Sandison, alongside colleague Margot Cutner, developed groundbreaking LSD therapy protocols incorporating Jungian principles. Their work in the 1950s revealed profound connections between psychedelic experiences and spiritual rebirth themes, bridging ancient wisdom with modern psychiatry.
Abstract
C. G. Jung wrote very little about psychedelic drugs and he took a sceptical view of them. However, he was sufficiently impressed by Aldous Huxley'...
Stutterers' experiences on classic psychedelics: A preliminary self-report study.
Journal of fluency disorders – September 01, 2024
Summary
Online discussions reveal promising connections between psychedelics and stuttering relief. Analysis of Reddit posts shows 74% of people who stutter reported reduced symptoms after using psilocybin or LSD. The qualitative study examined 114 self-reported experiences, finding improvements in speech fluency, social anxiety, and emotional well-being among most users.
Abstract
Stuttering poses challenges to social, occupational, and educational aspects of life. Traditional behavioral therapies can be helpful but effects a...
Divergent Effects of Ketamine and the Serotoninergic Psychedelic 2,5-Dimethoxy-4-Iodoamphetamine on Hippocampal Plasticity and Metaplasticity.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
While ketamine and psychedelics both help treat mental health conditions, their effects on brain plasticity differ significantly. New research reveals that the psychedelic DOI enhances brain cell communication in the hippocampus 24 hours after treatment, while ketamine shows no such effect. DOI appears to work by boosting signal transmission between neurons, suggesting unique mechanisms for these promising therapeutic compounds.
Abstract
Serotonergic psychedelics and ketamine produce rapid and long-lasting symptomatic relief in multiple psychiatric disorders. Evidence suggests that ...
Patients' Experiences Discussing Psychedelics for Therapeutic Purposes with Physicians and Other Health Care Providers.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
Despite growing interest in psychedelics for therapeutic purposes, 70% of users never discuss these treatments with their doctors. A survey of 791 adults revealed that while 80% used psychedelics with therapeutic intent, most avoid physician communication due to stigma and legal concerns. Those with mood disorders or PTSD were more likely to discuss plant medicine with healthcare providers, highlighting the need to reduce barriers to access and improve patient-doctor dialogue.
Abstract
A core component in the provision and receipt of appropriate medical care is trust and communication between patients and physicians. The use of ps...
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review.
Pharmacology, biochemistry, and behavior – September 01, 2024
Summary
Cardiac surgery patients face a startling 40% risk of perioperative depression, but breakthrough treatments offer hope. The rapid-acting medications ketamine and its refined version esketamine are transforming depression care in anesthesiology. While traditional antidepressants take weeks to work, these medications can provide relief within hours by targeting brain glutamate systems. Studies show both options effectively reduce depression symptoms, with esketamine offering fewer side effects.
Abstract
Depression is a significant factor contributing to postoperative occurrences, and patients diagnosed with depression have a higher risk for postope...
Bioisosteric analogs of MDMA: Improving the pharmacological profile?
Journal of neurochemistry – September 01, 2024
Summary
Scientists have developed promising alternatives to MDMA that maintain its therapeutic benefits while potentially reducing unwanted side effects. These new compounds work similarly to MDMA in targeting brain chemical transporters but show decreased activity at certain serotonin receptors. They also break down differently in the liver, which could mean fewer adverse effects. This advancement may help expand treatment options for PTSD and other mental health conditions.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is re-emerging in clinical settings as a candidate for the treatment of specific neuropsychiatr...
Potential effect of ketamine in treatment for dextromethorphan use disorder exploding in Japanese young population.
Asian journal of psychiatry – September 01, 2024
Summary
Young Japanese adults seeking relief from depression and trauma are increasingly misusing dextromethorphan, a common over-the-counter medication. Research shows ketamine therapy could offer a safer, clinically-supervised alternative for these individuals who turn to self-medication. The treatment shows promise in addressing both addiction and underlying mental health concerns.
Abstract
In Japan, the landscape of clinical practice for substance use disorder is changing significantly, primarily due to an increase in patients using o...
Exploring perinatal ketamine for postpartum depression following cesarean section: A systematic review.
PCN reports : psychiatry and clinical neurosciences – September 01, 2024
Summary
Promising new evidence suggests that perinatal ketamine could offer relief for new mothers experiencing postpartum depression after cesarean sections. When administered during C-sections, this medication showed significant potential in reducing depression symptoms in most studies. Analysis of multiple clinical trials revealed lower depression scores in mothers who received ketamine compared to those who didn't, offering hope for safer, more effective treatment options.
Abstract
The aim of this study was to explore the use of perinatal ketamine to see if it can be used for the reduction of postpartum depression (PPD) follow...
A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression.
Asian journal of psychiatry – September 01, 2024
Summary
Oral ketamine shows promise as a more convenient alternative to intravenous treatment for severe depression. In a groundbreaking comparison, patients receiving oral ketamine were more likely to complete their treatment course and reported fewer side effects than those receiving IV doses. Both methods showed similar effectiveness in reducing depressive symptoms, with oral administration causing less drowsiness and fewer headaches.
Abstract
For depression, ketamine is more conveniently administered by oral than by intravenous (iv) routes. The relative antidepressant efficacy of oral vs...
Different development patterns of reward behaviors induced by ketamine and JWH-018 in striatal GAD67 knockdown mice.
Journal of veterinary science – September 01, 2024
Summary
Ketamine's addictive effects may be influenced by specific brain chemicals. Scientists found that reducing GAD67, an enzyme that produces gamma-aminobutyric acid, in the brain's reward center made mice more susceptible to ketamine addiction but not to synthetic cannabis (JWH-018). This suggests GAD67 plays a key role in how the brain responds to different drugs.
Abstract
Glutamic acid decarboxylase 67 (GAD67) is a gamma-aminobutyric acid (GABA) synthesis enzyme associated with the function of other neurotransmitter ...
Nurses' Perceptions of Psychedelics to Address Mental Health Problems in the United States.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
Nearly half of Minnesota nurses support the decriminalization of psychedelics for mental health treatment, with 45.7% in favor. In a survey of 1,133 registered nurses, 80.7% expressed interest in observing psychedelic therapy sessions, while 74.1% recognized the importance of nursing roles in this emerging field. However, only 26.5% felt confident about the benefits of psychedelics, highlighting a need for enhanced education and competency development to ensure effective support for psychedelic treatments addressing conditions like depression and PTSD.
Abstract
To explore nurses' knowledge, attitudes, and perceived social norms about psychedelic use to address mental health conditions. Data were collected ...
Shared effects of electroconvulsive shocks and ketamine on neuroplasticity: A systematic review of animal models of depression.
Neuroscience and biobehavioral reviews – September 01, 2024
Summary
Both ketamine and electroconvulsive therapy show remarkable success in treating severe depression by boosting brain plasticity. These treatments increase BDNF protein levels and stimulate new neuron growth in the hippocampus. The treatments enhance brain cell connections and improve neurotransmitter function, suggesting they work through similar mechanisms to rapidly lift depression symptoms.
Abstract
Electroconvulsive shocks (ECS) and ketamine are antidepressant treatments with a relatively fast onset of therapeutic effects compared to conventio...
EEG signature of near-death-like experiences during syncope-induced periods of unresponsiveness.
NeuroImage – September 01, 2024
Summary
Fainting can trigger dream-like experiences resembling near-death experiences (NDEs) in some individuals. In a study involving 27 healthy volunteers, high-density EEG captured brain activity during induced unresponsiveness lasting about 22 seconds. Eight participants reported NDE-like features, scoring above 7 on the Greyson NDE scale. These experiences correlated with heightened neural activity in delta, theta, and beta2 bands, particularly in the temporal and frontal regions. Notably, those reporting NDE-like episodes displayed greater neural complexity and connectivity compared to others, suggesting distinct markers of consciousness disconnect.
Abstract
During fainting, disconnected consciousness may emerge in the form of dream-like experiences. Characterized by extra-ordinary and mystical features...
Effect of esketamine combined with pregabalin on acute postsurgical pain in patients who underwent resection of spinal neoplasms: a randomized controlled trial.
Pain – September 01, 2024
Summary
A promising pain management breakthrough shows that combining two medications can significantly reduce severe post-surgical pain in spine surgery patients. In this groundbreaking approach, patients receiving esketamine with pregabalin experienced less than half the rate of moderate-to-severe pain compared to those receiving standard care. While the treatment proved highly effective, some patients reported mild dissociative effects - a trade-off many might consider worthwhile for superior pain control.
Abstract
Moderate-to-severe acute postsurgical pain (APSP) can prolong the recovery and worsen the prognosis of patients who undergo spinal surgery. Esketam...
The Therapeutic Potential of Psychedelics on Reducing Rumination: A Mini-Review.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
Psychedelic use is linked to significantly lower levels of rumination, a major risk factor for depression and anxiety. In a review of six studies, it was found that individuals using psychedelics experienced reduced repetitive negative thinking, which may enhance treatment outcomes for various mental health disorders. With sample sizes varying across studies, the evidence highlights the importance of addressing rumination before psychedelic sessions. Strategies like mindfulness and cognitive behavior therapy could further support long-term mental health maintenance post-treatment.
Abstract
Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and is associated with various other forms of ...
Neurocognitive changes in a patient receiving esketamine for treatment-resistant depression.
JAAPA : official journal of the American Academy of Physician Assistants – September 01, 2024
Summary
A groundbreaking depression treatment showed unexpected effects on brain function in one patient. Doctors observed cognitive changes in a person using intranasal esketamine spray for severe depression. While the medication improved mood, it led to memory and thinking difficulties that worsened over time. This rare case highlights the importance of monitoring cognitive function during innovative depression treatments.
Abstract
Esketamine, the s(+) enantiomer of ketamine, was approved in 2019 as the first rapid-acting intranasal spray medication for treatment-resistant dep...
Ketamine for catatonia: A novel treatment for an old clinical challenge? A systematic review of the evidence.
Schizophrenia research – September 01, 2024
Summary
Ketamine, traditionally used as an anesthetic, shows remarkable promise in treating catatonia - a complex condition where patients become unresponsive or display unusual movements. New research reveals an 80% response rate when using ketamine or esketamine treatments, with particularly strong results in patients who have underlying mood disorders. This breakthrough offers hope for those who don't respond to standard treatments.
Abstract
Catatonia, documented since the 19th century, remains a significant challenge in terms of recognition and treatment. Over the last two decades, ket...
MDMA("Ecstasy") abuse leading to delayed onset rhabdomyolysis: A case report and literature review.
Clinical case reports – September 01, 2024
Summary
MDMA use can trigger muscle breakdown (rhabdomyolysis) not just immediately, but days after exposure. This report details a case where delayed muscle damage led to dangerously high creatine kinase levels and acute kidney injury (AKI). Early recognition and treatment were crucial for the patient's recovery, highlighting the importance of monitoring MDMA users for delayed complications.
Abstract
MDMA and cocaine can result in acute onset rhabdomyolysis. However, delayed onset rhabdomyolysis and its pathophysiology is of concern Early therap...
Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs.
Psychiatry research – September 01, 2024
Summary
When traditional antidepressants fail, innovative therapies like ketamine and psilocybin show remarkable promise. A comprehensive network meta-analysis of 72 clinical trials reveals that these enhanced treatments, along with ECT, offer the best outcomes for treatment-resistant depression. Among 12,000+ patients studied, these approaches demonstrated superior effectiveness while maintaining acceptable safety profiles.
Abstract
Treatment-Resistant Depression (TRD) challenges psychiatric treatment, with existing guidelines covering only a subset of augmentation strategies. ...
Ketamine's mechanism of action with an emphasis on neuroimmune regulation: can the complement system complement ketamine's antidepressant effects?
Molecular psychiatry – September 01, 2024
Summary
The rapid antidepressant effects of ketamine - working within hours instead of weeks - mark a breakthrough in treating severe depression. New research reveals ketamine's effectiveness may be linked to its unique ability to regulate both brain inflammation and immune system responses. By modulating specific immune components called the complement system, ketamine helps restore healthy brain cell communication and reduces inflammation associated with depression. This dual action explains why it can provide relief when traditional antidepressants fail.
Abstract
Over 300 million people worldwide suffer from major depressive disorder (MDD). Unfortunately, only 30-40% of patients with MDD achieve complete rem...
Psychotropic Drugs Reemerging as Headache Medicines.
CNS drugs – September 01, 2024
Summary
Recent findings reveal that certain psychedelic compounds show promise in treating severe headache disorders. Doctors report that carefully controlled doses of substances like psilocybin and ketamine may help patients who haven't responded to conventional treatments. These medications appear to work by disrupting pain pathways and reducing inflammation in the brain. Early clinical results suggest some patients experience months of relief from a single treatment.
Abstract
Scientific and public attention on the therapeutic effects of psychedelics and other psychoactive compounds in headache disorders has recently grow...
Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.
Molecular psychiatry – September 01, 2024
Summary
A breakthrough in depression treatment may lie in personalized dosing: while fixed low-dose oral esketamine showed limited benefits, individually tailored higher doses significantly reduced symptoms in treatment-resistant patients. In a rigorous trial, patients receiving customized doses saw depression scores drop by 6 points on average, offering hope for those who haven't responded to conventional treatments.
Abstract
About one-third of patients with depression do not achieve adequate response to current treatment options. Although intravenous and intranasal admi...
Diurnal variation of postoperative delirium in elderly patients undergoing esketamine anesthesia for elective noncardiac surgery: a randomized clinical trial.
International journal of surgery (London, England) – September 01, 2024
Summary
Afternoon surgeries may reduce delirium risk in elderly patients by nearly 45%, according to new findings. In a study of 426 patients aged 65-85 undergoing non-cardiac surgery, those operated on between 2-6 PM showed significantly lower rates of post-surgery confusion compared to morning procedures. While a pre-surgery dose of esketamine didn't affect delirium rates, it did help prevent low blood pressure during surgery.
Abstract
Postoperative delirium (POD) is a serious and common complication. The aim of present study is to investigate the diurnal variation of POD and the ...
Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
Underground psychedelic facilitators report that personal healing experiences with substances like psilocybin, LSD, and MDMA drive their commitment to helping others. Their insights reveal consistent yet adaptable therapeutic approaches, emphasizing the client's innate healing capacity. While supporting broader access to psychedelic medicine, these practitioners express concern about over-standardization limiting the personalized care that makes their work effective.
Abstract
There is increasing interest in the use of psychedelics for therapeutic and recreational use. Research has been hindered by federal prohibition, pu...
Entactogen Effects of Ketamine: A Reverse-Translational Study.
The American journal of psychiatry – September 01, 2024
Summary
Ketamine, a breakthrough antidepressant, shows remarkable potential in enhancing social connection and empathy. Recent findings reveal that people with treatment-resistant depressive disorders reported increased pleasure from social interactions for a full week after receiving ketamine treatment. Like MDMA and other entactogens, ketamine boosted enjoyment of time with family, seeing smiles, and helping others. Even lab rats showed more compassion, choosing to protect companions over receiving rewards.
Abstract
The authors sought to assess the prosocial, entactogen effects of ketamine. Pleasure from social situations was assessed in a sample of participant...
Antagonistic interaction between caffeine and ketamine in zebrafish: Implications for aquatic toxicity.
Environmental science and ecotechnology – September 01, 2024
Summary
When caffeine and ketamine mix in water, they create an unexpected interaction: ketamine actually reduces caffeine's harmful effects on fish. In lab tests, ketamine counteracted caffeine-induced hyperactivity in zebrafish by interacting with GABAergic synapses in their brains. This antagonistic effect lowered developmental problems from 27% to 7%, showing how common water contaminants can interact in surprising ways.
Abstract
The coexistence of caffeine (CF) and ketamine (KET) in surface waters across Asia has been widely reported. Previous studies have implied that CF a...
Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.
Current medical research and opinion – September 01, 2024
Summary
Insurance requirements for esketamine, a breakthrough nasal spray for treatment-resistant depression, may be unnecessarily strict. Data shows patients typically try 4 antidepressants before seeking this treatment, far exceeding standard requirements. Analysis of 568 patients revealed similar treatment patterns regardless of insurance criteria, with most having used multiple medications and antipsychotics for their depression.
Abstract
In the United States (US), prescription drug coverage is subject to prior authorization (PA) criteria, which may vary between health plans and may ...
Ketamine versus electroconvulsive therapy for major depressive episode: An updated systematic review and non-inferiority meta-analysis.
Psychiatry research – September 01, 2024
Summary
The anesthetic ketamine shows promise as an antidepressant, but may not match electroconvulsive therapy's effectiveness for severe depression. Analysis of 655 patients revealed that while ketamine caused fewer cognitive side effects and less muscle pain, ECT produced stronger improvements in depression symptoms, particularly for hospitalized patients with major depressive disorder. Both treatments remain valuable options for treating mood disorders.
Abstract
We conducted a systematic review and meta-analysis to investigate the comparative effectiveness of ketamine versus electroconvulsive therapy (ECT) ...
Effect of a subanesthetic dose of esketamine combined with propofol on postoperative fatigue syndrome in patients undergoing gastroenterological endoscopy under anaesthesia: A retrospective study.
Pakistan journal of medical sciences – September 01, 2024
Summary
A promising breakthrough in endoscopy recovery shows that combining a small dose of esketamine with standard anesthesia significantly reduces post-procedure fatigue. In a 160-patient analysis, those receiving esketamine with propofol experienced faster recovery times and less postoperative fatigue syndrome compared to traditional methods. The combination also resulted in better vital signs and fewer complications during gastroenterological endoscopy.
Abstract
To assess the effect of subanesthetic dose of esketamine in combination with propofol on the incidence of postoperative fatigue syndrome (POFS) in ...
Ayahuasca Treatment Outcome Project (ATOP): One-Year Results from Takiwasi Center and Implications for Psychedelic Science.
Journal of studies on alcohol and drugs – September 01, 2024
Summary
A unique Peruvian treatment center combining ayahuasca ceremonies with traditional therapy shows promising results for addiction recovery. After one year, participants demonstrated significant improvements in substance use, anxiety, depression, and quality of life. Most patients rated the spiritual aspects of ayahuasca experiences as highly meaningful in their healing journey.
Abstract
This article focuses on the outcomes at 1 year post-treatment of a naturalistic evaluation of services provided through the Takiwasi Centre, an acc...
Treatment-emergent symptoms during short-term ketamine administration in treatment-resistant bipolar depression: A retrospective cross-sectional descriptive study.
Asian journal of psychiatry – September 01, 2024
Summary
Ketamine shows promise in treating bipolar depression, but understanding its side effects is crucial. In patients receiving ketamine infusions while maintaining their regular medications, new symptoms emerged during treatment. Common effects included changes in appetite, weight fluctuations, and altered sleep patterns. While mood improvements were noted, careful monitoring is vital as some patients reported suicidal thoughts. These findings help doctors better anticipate and manage side effects in bipolar disorder treatment.
Abstract
Symptoms that emerge during pharmacological treatment of bipolar depression are frequently observed, underscoring the necessity for comprehensive t...
Perspectives and preliminary experiences of psychedelics for the treatment of eating disorders: A systematic scoping review.
European eating disorders review : the journal of the Eating Disorders Association – September 01, 2024
Summary
A significant finding indicates that most participants in studies reported a meaningful reduction in eating disorder symptoms after psychedelic-assisted psychotherapy. Out of 1,290 initial publications, only 17 met the eligibility criteria, highlighting substantial gaps in research. While many expressed openness to psychedelics as a treatment option, concerns about potential adverse effects and the necessity for psychological support were noted. This emerging evidence suggests that psychedelics could be a promising avenue for treating eating disorders, though more rigorous studies are essential to validate these findings.
Abstract
Research regarding the therapeutic application of psychedelics and psychedelic-assisted psychotherapy in the treatment of eating disorders (EDs) ha...
Intellectual Property of Psychedelics for Addiction Treatment: Enabling Access and Protecting Innovation Opportunities Through Preserving the Public Domain.
Journal of studies on alcohol and drugs – September 01, 2024
Summary
Psychedelic compounds show promise as addiction treatments, but 170 patent documents threaten to monopolize this potential. These patents could limit public access to important knowledge and increase research costs. Patent examiners face challenges in identifying prior art due to the complex history of psychedelics, which may lead to unjustified patents being granted. As the FDA approaches key decisions, it is vital for all stakeholders—academics, patent seekers, and policymakers—to understand patent eligibility and limitations to ensure equitable access to these transformative therapies.
Abstract
Recent research has shown potential for psychedelic therapeutics as addiction treatments; however, some academic institutions, commercial entities,...
Neurophenomenological Investigation of Mindfulness Meditation "Cessation" Experiences Using EEG Network Analysis in an Intensively Sampled Adept Meditator.
Brain topography – September 01, 2024
Summary
A remarkable finding reveals that an advanced meditator experienced 37 cessation events during over 6,000 hours of mindfulness training. Using electroencephalography (EEG) across 29 sessions, significant brain activity changes were observed: large-scale functional interactions in the alpha band decreased 21 seconds before cessations and returned to baseline within 40 seconds after. This shift was characterized by reduced connectivity from frontal to left temporal regions, suggesting a profound transformation in brain function linked to deep mindfulness meditation and its potential benefits for mental health and well-being.
Abstract
Mindfulness meditation is a contemplative practice that is informed by Buddhism. It has been proven effective for improving mental and physical hea...
Newer Treatments for Mood and Anxiety Disorders.
The Medical clinics of North America – September 01, 2024
Summary
Antidepressants like serotonin reuptake inhibitors have dominated treatment for depression and anxiety for over two decades. While newer medications with innovative mechanisms are available, first-line treatments remain unchanged. Recent data, encompassing thousands of patients, highlight the effectiveness of various augmentation agents in managing major depressive disorder, offering improved guidance for primary care providers. However, evidence supporting psychedelic-assisted psychotherapy is still insufficient to warrant widespread adoption for mood and anxiety disorders, emphasizing the need for continued evaluation of these novel treatments.
Abstract
For more than 20 years, the mainstay of pharmacologic treatment for depression and anxiety disorders has been serotonin reuptake inhibitors and sel...
The effectiveness of mindfulness-based cognitive therapy during poststroke rehabilitation: a randomized controlled trial.
International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation – September 01, 2024
Summary
Mindfulness-based cognitive therapy (MBCT) showed promise in enhancing mindfulness among stroke survivors, with significant improvements in the observing subscale. In a randomized trial involving 93 post-stroke patients, 80 completed the study: 43 received MBCT alongside standard care and 37 received only standard care. Despite no significant changes in depression or anxiety levels, the intervention group demonstrated increased trait mindfulness. The findings suggest that while MBCT may not reduce psychological distress, it can positively influence certain mindfulness aspects during rehabilitation.
Abstract
Stroke can have a range of physical, psychological, cognitive, and social impacts that are challenging for survivors. This study aimed to evaluate ...